ProCE Banner Activity

An Expert’s Guide to SABCS 2024: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Review this preview commentary on expert-selected top abstracts to watch at the 2024 San Antonio Breast Cancer Symposium, some with the potential to change the current treatment landscape of patients with breast cancer.

Released: December 06, 2024

Expiration: December 05, 2025

Share

Faculty

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Commitee
Sarah Cannon Research Institute
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH: consultant/advisor/speaker: AstraZeneca, Gilead, Lilly, Merck, Moderna, Novartis, Pfizer.

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Commitee
Sarah Cannon Research Institute
Dallas, Texas

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, Bydonis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, Dava Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru.